Good afternoon, everyone, and welcome to our first quarter of 2026 earnings call. Bob Bradway will lead the call today and be followed by a broader review of our performance by Murdo Gordon, Jay ...

Phase 2/3 registrational trial (OptimUM-02) of darovasertib combination met its primary endpoint; complete data will be provided in a late-breaking oral presentation ...

Discusses Modulation and Combination Strategies in ER-Positive Metastatic Breast Cancer and the Role of Lasofoxifene April 29, ...

Five novel inhibitors of the MenT3 toxin were identified through a machine learning and simulations pipeline, offering new ...

Drug discovery still too often relies on expensive trial and error. Researchers from ICTER show there is another way—building ...

Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced ...

Discover how quality-driven drug development and AI accelerate safer medicines, reduce risk, and improve patient outcomes.

Resolving the mechanism of RXR ligand-dependent NR4A-RXR nuclear receptor heterodimer activation requires a diverse ligand set that includes heterodimer-selective agonists.

Mortality disparities among people of different genetic ancestries are increasing, highlighting the need for more diverse ...

Accelerated drug development expertise. For small startups and academic spinoffs bringing their first molecules to market, ...

Company on track to initiate a randomized, double-blind, placebo-controlled, adaptive Phase 2 field study in the first half of 2027, pending FDA ...

Meanwhile, peroxisome proliferation-activated receptors (PPARs) are obesity drug targets in their own right: activating them can reduce inflammation and restore insulin sensitivity. But molecules that ...